PT  - JOURNAL ARTICLE
AU  - Williams, A
AU  - Davies, S
AU  - Stuart, A G
AU  - Wilson, D G
AU  - Fraser, A G
TI  - Medical treatment of Marfan syndrome: a time for change
AID  - 10.1136/hrt.2006.109454
DP  - 2008 Apr 01
TA  - Heart
PG  - 414--421
VI  - 94
IP  - 4
4099  - http://heart.bmj.com/content/94/4/414.short
4100  - http://heart.bmj.com/content/94/4/414.full
SO  - Heart2008 Apr 01; 94
AB  - It is accepted practice to prescribe β-blockers in order to retard aortic dilatation and prevent aortic dissection and rupture in patients with Marfan syndrome. A critical review of the published pharmacological studies shows this practice to be based on limited evidence. The data from small clinical and experimental studies with surrogate end points suggest greater potential benefit from alternative drug regimens, and a recent experimental study showed that losartan may interrupt the mechanism of disease as well as deal with its functional consequences. It is now essential to perform large, collaborative, randomised controlled trials with clinical end points of new treatments in Marfan syndrome.